Medical Developments International Limited
(ASX:MVP) has announced the Canadian regulatory body, Health Canada, has accepted its Penthrox regulatory dossier for review.
The healthcare product company says accepting the single use inhaler device for review, triggers a milestone payment to be made to the company.
Medical Developments International is set to receive a quarter of a million Canadian dollars [CAD$0.25 million] from its partner, Purdue Pharma (Canada).
The company says it is a positive step towards globalising its product, Penthrox.
Shares in Medical Developments International Limited
(ASX:MVP) are trading 0.93 per cent lower to $5.34.